专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07732404B2 Pro-nanodispersion for the delivery of cyclosporin 失效
标题翻译：用于递送环孢菌素的准纳米分散体
公开(公告)号：US07732404B2
公开(公告)日：2010-06-08
申请号：US11363379
申请日：2006-02-28
申请人： Abraham J. Domb , Avi Avramoff , Victor Pevzner
发明人： Abraham J. Domb , Avi Avramoff , Victor Pevzner
IPC分类号： A61K38/13
CPC分类号： A61K9/0048 , A61K9/1075 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K38/13
摘要： A novel cyclosporine formulation, which is a pro-nanodispersion at room temperature, featuring solid particles of a relatively large particle size (at least about 150 nm) and yet which is a nanodispersion at body temperature.
摘要翻译：一种新颖的环孢菌素制剂，其在室温下是原分散体，其特征在于具有相对较大粒度（至少约150nm）的固体颗粒，并且其在体温下是纳米分散体。

2. 发明申请

US20060205639A1 Pro-nanodispersion for the delivery of cyclosporin 失效
标题翻译：用于递送环孢菌素的准纳米分散体
公开(公告)号：US20060205639A1
公开(公告)日：2006-09-14
申请号：US11363379
申请日：2006-02-28
申请人： Abraham Domb , Avi Avramoff , Victor Pevzner
发明人： Abraham Domb , Avi Avramoff , Victor Pevzner
IPC分类号： A61K38/13
CPC分类号： A61K9/0048 , A61K9/1075 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K38/13
摘要： A novel cyclosporine formulation, which is a pro-nanodispersion at room temperature, featuring solid particles of a relatively large particle size (at least about 150 nm) and yet which is a nanodispersion at body temperature.
摘要翻译：一种新颖的环孢菌素制剂，其在室温下是原分散体，其特征在于具有相对较大粒度（至少约150nm）的固体颗粒，并且其在体温下是纳米分散体。

3. 发明授权

US08105627B2 Extended release venlafaxine tablet formulation 有权
标题翻译：延长释放文拉法辛片剂
公开(公告)号：US08105627B2
公开(公告)日：2012-01-31
申请号：US10555310
申请日：2003-12-11
申请人： Sima Volpert , Avi Avramoff
发明人： Sima Volpert , Avi Avramoff
IPC分类号： A61K9/28
CPC分类号： A61K9/2866 , A61K9/2054 , A61K31/137
摘要： An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer. The core is preferably coated with a coating material. The coating preferably contains a mixture of water soluble cellulosic polymer and a water insoluble cellulosic polymer. According to a first embodiment of the present invention, the filler is preferably present in an amount of at least about 40% weight per weight of the total formulation. More preferably, the filler comprises microcrystalline cellulose. Most preferably, the filler solely comprises microcrystalline cellulose. Also most preferably, microcrystalline cellulose is present in the core in a range of from about 45% to about 65% weight per weight of the total formulation.
摘要翻译：用于口服片剂剂型中文拉法辛的延长释放制剂。制剂优选具有芯，其上层叠有外涂层。核心优选含有文拉法辛，填充剂和水溶性纤维素聚合物，任选且更优选含有水不溶性纤维素聚合物。芯优选用涂料涂覆。涂层优选含有水溶性纤维素聚合物和水不溶性纤维素聚合物的混合物。根据本发明的第一个实施方案，填料优选以总制剂重量至少约40重量％的量存在。更优选地，填料包括微晶纤维素。最优选地，填料仅包含微晶纤维素。最优选地，微晶纤维素以总配方重量的约45重量％至约65重量％存在于芯中。

4. 发明申请

US20110052690A1 PROCESS FOR MANUFACTURE OF A MEDICAMENT WITH GRANULATION AND PAN COATING 审中-公开
标题翻译：具有颗粒和PAN涂层的药物的制备方法
公开(公告)号：US20110052690A1
公开(公告)日：2011-03-03
申请号：US12935808
申请日：2009-06-01
申请人： Avi Avramoff , Sima Volpert
发明人： Avi Avramoff , Sima Volpert
IPC分类号： A61K9/28
CPC分类号： A61K9/2866 , A61K9/2054 , A61K31/137
摘要： A process for the manufacture of a coated tablet comprising a serotonin-norepinephrine reuptake inhibitor (SNRI), such as venlafaxine. According to one embodiment of the present invention, there is provided a process for manufacturing a coated tablet containing a serotonin-norepinephrine reuptake inhibitor, the process comprising preparing a granulate of the serotonin-norepinephrine reuptake inhibitor using a low shear granulator; compressing the granulation into a core; and applying a coating to the core using a pan coater.
摘要翻译：一种制备包含血清素 - 去甲肾上腺素再摄取抑制剂（SNRI），如文拉法辛的包衣片剂的方法。根据本发明的一个实施方案，提供了一种制备含有5-羟色胺去甲肾上腺素再摄取抑制剂的包衣片剂的方法，该方法包括使用低剪切制粒机制备5-羟色胺 - 去甲肾上腺素再摄取抑制剂的颗粒; 将造粒压成芯; 并使用泛涂布机将涂层施加到芯上。

5. 发明申请

US20100297226A1 MULTIPLE UNIT PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：多部门药物制剂
公开(公告)号：US20100297226A1
公开(公告)日：2010-11-25
申请号：US12227864
申请日：2007-06-03
申请人： Adel Penhasi , Sheera Moses-Heller , Mila Gomberg , Avi Avramoff
发明人： Adel Penhasi , Sheera Moses-Heller , Mila Gomberg , Avi Avramoff
IPC分类号： A61K31/4439 , A61K9/20 , A61K9/28 , A61K9/40 , A61K31/4184 , A61P1/04
CPC分类号： A61K9/2886 , A61K9/2077 , A61K9/5026 , A61K9/5042 , A61K31/4439
摘要： An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer.
摘要翻译：口服崩解的苯并咪唑制剂，其特征在于MUPS片剂中的多个压缩颗粒。单个单元具有含有活性成分的底物和肠溶衣，任选地在底物和肠溶衣之间具有底衣。各个单元优选地至少部分地涂覆有具有应力吸收体的外涂层，从而使得可以压缩颗粒而不干扰肠溶衣的完整性。肠溶衣优选不具有增塑剂。

6. 发明申请

US20110052648A1 ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES 审中-公开
标题翻译：含有THIAZEPINES的口服修饰释放配方
公开(公告)号：US20110052648A1
公开(公告)日：2011-03-03
申请号：US12921168
申请日：2009-03-09
申请人： Avi Avramoff , Adel Penhasi , Orly Einav-Rubashkin , Ron Schlinger
发明人： Avi Avramoff , Adel Penhasi , Orly Einav-Rubashkin , Ron Schlinger
IPC分类号： A61K31/554 , A61K9/00 , A61P25/22 , A61P25/18 , A61P25/24
CPC分类号： A61K9/1635 , A61K9/284 , A61K9/2846 , A61K31/554
摘要： An oral modified-release formulation using Quetiapine or pharmaceutically acceptable salts thereof as an active ingredient, while avoiding the use of a gelling material. As used herein, the term “modified release” includes but is not limited to one or more of controlled release, sustained release, prolonged release and extended release.
摘要翻译：使用喹硫平或其药学上可接受的盐作为活性成分的口服改良释放制剂，同时避免使用胶凝材料。如本文所用，术语“修饰释放”包括但不限于控制释放，缓释，延长释放和延长释放中的一种或多种。

7. 发明申请

US20110038933A1 STABLE BENZIMIDAZOLE FORMULATION 审中-公开
标题翻译：稳定的苯并咪唑配方
公开(公告)号：US20110038933A1
公开(公告)日：2011-02-17
申请号：US12866255
申请日：2009-05-05
申请人： Valerie Azoulay , Avi Avramoff , Adel Penhasi , Maxim Gomberg
发明人： Valerie Azoulay , Avi Avramoff , Adel Penhasi , Maxim Gomberg
IPC分类号： A61K9/28 , A61K9/00 , A61K9/14 , A61K31/4439 , A61P1/04
CPC分类号： A61K9/2095 , A61K9/1676 , A61K9/282 , A61K9/2866 , A61K9/5042 , A61K31/4439
摘要： A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
摘要翻译：一种苯并咪唑制剂，其缺乏中间层，而且在储存期间和在通过胃期间都是稳定的，并且具有低水平的残留挥发性赋形剂，包括但不限于残留的碱化剂和/或残留溶剂。

8. 发明申请

US20100278909A1 PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS 审中-公开
标题翻译：形成ANGIOTENSIN II受体拮抗剂固体口服剂型的方法
公开(公告)号：US20100278909A1
公开(公告)日：2010-11-04
申请号：US12663288
申请日：2008-05-29
申请人： Ron Schlinger , Avi Avramoff
发明人： Ron Schlinger , Avi Avramoff
IPC分类号： A61K31/41 , A61K31/549 , A61P9/12 , A61P13/12 , A61P9/08 , A61K9/28 , A61K9/48
CPC分类号： A61K31/41 , A61K9/146 , A61K9/1641 , A61K9/1652 , A61K9/1694 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2095 , A61K9/2846 , A61K31/64 , A61K2300/00
摘要： A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting point of the melt granulating agent to form a solid dispersion of the angiotensin II receptor antagonist in the melt granulating agent; and c) cooling the solid dispersion to form granules; wherein the melt granulating agent is the only granulating agent used to form the granules.
摘要翻译：一种生产血管紧张素II受体拮抗剂或其药学上可接受的盐的颗粒的方法，其包括：a）将血管紧张素II受体拮抗剂或其药学上可接受的盐与熔融制粒剂混合以形成混合物; b）将混合物的温度升高到熔融制粒剂的熔点，以形成熔体制粒剂中血管紧张素II受体拮抗剂的固体分散体; 和c）冷却固体分散体以形成颗粒; 其中熔融制粒剂是用于形成颗粒的唯一造粒剂。

9. 发明申请

US20070082049A1 Extended release venlafaxine tablet formulation 有权
标题翻译：延长释放文拉法辛片剂
公开(公告)号：US20070082049A1
公开(公告)日：2007-04-12
申请号：US10555310
申请日：2003-12-11
申请人： Sima Volpert , Avi Avramoff
发明人： Sima Volpert , Avi Avramoff
IPC分类号： A61K9/22
CPC分类号： A61K9/2866 , A61K9/2054 , A61K31/137
摘要： An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer. The core is preferably coated with a coating material. The coating preferably contains a mixture of water soluble cellulosic polymer and a water insoluble cellulosic polymer. According to a first embodiment of the present invention, the filler is preferably present in an amount of at least about 40% weight per weight of the total formulation. More preferably, the filler comprises microcrystalline cellulose. Most preferably, the filler solely comprises microcrystalline cellulose. Also most preferably, microcrystalline cellulose is present in the core in a range of from about 45% to about 65% weight per weight of the total formulation.
摘要翻译：用于口服片剂剂型中文拉法辛的延长释放制剂。制剂优选具有芯，其上层叠有外涂层。核心优选含有文拉法辛，填充剂和水溶性纤维素聚合物，任选且更优选含有水不溶性纤维素聚合物。芯优选用涂料涂覆。涂层优选含有水溶性纤维素聚合物和水不溶性纤维素聚合物的混合物。根据本发明的第一个实施方案，填料优选以总制剂重量至少约40重量％的量存在。更优选地，填料包括微晶纤维素。最优选地，填料仅包含微晶纤维素。最优选地，微晶纤维素以总配方重量的约45重量％至约65重量％存在于芯中。

10. 发明申请

US20060057204A1 Pharmaceutical compositions containing venlafaxine 审中-公开
标题翻译：含有文拉法辛的药物组合物
公开(公告)号：US20060057204A1
公开(公告)日：2006-03-16
申请号：US10532407
申请日：2003-10-23
申请人： Adel Penhasi , Mila Gomberg , Avi Avramoff
发明人： Adel Penhasi , Mila Gomberg , Avi Avramoff
IPC分类号： A61K9/24
CPC分类号： A61K31/135 , A61K9/1635 , A61K9/1652 , A61K9/2077 , A61K9/286 , A61K9/2866 , A61K9/2886 , A61K9/5036 , A61K9/5042
摘要： The invention provides a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.
摘要翻译：本发明提供一种延迟的爆发释放制剂，其包含形成为压制片剂的核心和围绕该核心的外部涂层; 所述核心包含文拉法辛或其药学上可接受的盐，至少一种爆发控制剂和崩解剂; 并且所述外涂层包含水不溶性疏水性载体和水不溶但不亲水的颗粒物质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式